A soluble activin type IIA receptor induces bone formation and improves skeletal integrity (Q36657509)

15 August 2017

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity (English)

1 reference

15 August 2017

2

Ernesto Canalis

0 references

Mary L. Bouxsein

15

object named as

Mary L Bouxsein

1 reference

15 August 2017

R Scott Pearsall

1

1 reference

15 August 2017

Ernesto Canalis

2

1 reference

15 August 2017

Milton Cornwall-Brady

3

1 reference

15 August 2017

Kathryn W Underwood

4

1 reference

15 August 2017

Brendan Haigis

5

1 reference

15 August 2017

Jeffrey Ucran

6

1 reference

15 August 2017

Ravindra Kumar

7

1 reference

15 August 2017

Eileen Pobre

8

1 reference

15 August 2017

Asya Grinberg

9

1 reference

15 August 2017

Eric D Werner

10

1 reference

15 August 2017

Vaida Glatt

11

1 reference

15 August 2017

Lisa Stadmeyer

12

1 reference

15 August 2017

Deanna Smith

13

1 reference

15 August 2017

Jasbir Seehra

14

1 reference

15 August 2017

language of work or name

English

0 references

publication date

6 May 2008

1 reference

Proceedings of the National Academy of Sciences of the United States of America

15 August 2017

1 reference

15 August 2017

105

1 reference

15 August 2017

19

1 reference

15 August 2017

7082-7087

1 reference

BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Mechanisms of anabolic therapies for osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Anabolic agents and the bone morphogenetic protein pathway

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Bone morphogenetic proteins and their antagonists

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Biomechanical and molecular regulation of bone remodeling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

FSH directly regulates bone mass

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Skeletal overexpression of gremlin impairs bone formation and causes osteopenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Microdamage and bone strength

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Inhibin is an antagonist of bone morphogenetic protein signaling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Emerging therapies in osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Betaglycan binds inhibin and can mediate functional antagonism of activin signalling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin and inhibin binding to the soluble extracellular domain of activin receptor II.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Bone mass homeostasis and bisphosphonate action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin-binding protein from rat ovary is follistatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin A is an essential cofactor for osteoclast induction.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2383948

Activin enhances osteoclast-like cell formation in vitro

20 September 2018

1 reference

12 December 2020

Local administration of activin promotes fracture healing in the rat fibula fracture model

1 reference

12 December 2020

Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice

1 reference

12 December 2020

FSH versus estrogen: who's guilty of breaking bones?

1 reference

12 December 2020

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis

1 reference

12 December 2020

1 reference

12 December 2020

Inhibin A is an endocrine stimulator of bone mass and strength

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0711263105

1 reference

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

18460605

1 reference